Fig. 5.

Enhancement of cytotoxic T-lymphocyte activity by treatment with tumor lysate–pulsed dendritic cells and anti-CD27 antibody. CD8⁺ T cells separated from the splenocytes of RM-1 tumor–bearing mice (10 per group)—which either were not treated or were treated with tumor lysate–pulsed dendritic cells, anti-CD27 antibody, or a combination of tumor lysate–pulsed dendritic cells with anti-CD27 antibody—were stimulated in vitro with RM-1 tumor lysate–pulsed dendritic cells for 5 days. The primed CD8⁺ T cells (effector cells) were harvested and cocultured with ⁵¹Cr-labeled RM-1 tumor cells (target cells) at an effector-to-target cell ratio of 100:1 for 4 hours. Cytotoxic T-lymphocyte activity against RM-1 tumor cells was determined by the ⁵¹Cr release assay. Results were shown as the percentage of target cell lysis. *P < 0.05 compared with control group; **P < 0.05 compared with all other groups.